# Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

> **NCT00955292** · PHASE1 · TERMINATED · sponsor: **Cylene Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** Quarfloxin

## Key facts

- **NCT ID:** NCT00955292
- **Lead sponsor:** Cylene Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-12
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Modified dose schedule presented no advantage over previously studied schedule
- **Last updated:** 2009-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955292, "Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00955292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*